



# Production fo a safe EMCF-FMDV recombinant vaccine against FMD

Margot Carocci

## ► To cite this version:

Margot Carocci. Production fo a safe EMCF-FMDV recombinant vaccine against FMD. Building Bridges Workshop, Jul 2011, Bejing, China. 28 diapos. hal-02806663

HAL Id: hal-02806663

<https://hal.inrae.fr/hal-02806663>

Submitted on 6 Jun 2020

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# **Production of a safe EMCV-FMDV recombinant vaccine against FMD**

**Margot Carocci**

***UMR1161 (ANSES,ENVA,INRA) Maisons-Alfort, FRANCE***

# Plan

---

## Introduction

Why a recombinant vaccine EMCV-FMDV?

## Results

- I. production and characterization of EMCVΔ2A
- II. Virulence attenuation on human primary astrocytes
- III. Virulence attenuation on mice
- IV. Production EMCV-FMDV

## Conclusion

---

# Why a recombinant vaccine EMCV-FMDV?

---

- A live attenuated vaccine: fast and good protection
- Easy to produce less confinement, less expensive
- Distinguish easily vaccinated and infected animals

# Why a recombinant vaccine EMCV-FMDV?

---


## FMDV / EMCV

- *Picornaviridae* :
  - positive ssRNA, ~8kb
  - Structural and genomic organization similar
  - Encode a single polyprotein,
  - Similar viral cycle

They are the 2 Picornaviridae, of different genus (**Aphthovirus** / **Cardiovirus**), showing more similarity

# Why a recombinant vaccine EMCV-FMDV?

## Genomic organization





### Clivage sites

- ▲ 3C<sup>pro</sup>
- ◆ L<sup>pro</sup>
- 2A

# Why a recombinant vaccine EMCV-FMDV?

Development of a chimera EMCV-FMDV virus :

Production of an hybrid genome :



# Towards a safe vaccine

---

## **EMCV : Encephalomyocarditis virus**

Can infect many different animal species

Depending on the animal species and the viral strain, EMCV can cause

Myocarditis

Reproduction disorders

Diabetes

**Encephalitis**

=> Attenuation of EMCV virulence is needed

# Plan

---

## Introduction

Why a recombinant vaccine EMCV-FMDV?

## Results

- I. production and characterization of EMCV $\Delta$ 2A
- II. Virulence attenuation on human primary astrocytes
- III. Virulence attenuation on mice
- IV. Production EMCV-FMDV

## Conclusion


---

# I. EMCV $\Delta$ 2A production and characterization

B279 strain 210 passed on BHK-21 : non-virulent for pigs


(P.Denis and F. Koenen Arch Virol 2003)

Test virulence on mice C57Bl/6




C9 clone => a **deletion** in the **2A protein sequence**.

# I. EMCV $\Delta$ 2A production and characterization




Incorporation of a deletion in 2A, using a reverse genetic previously developed in our lab (Bakkali et al., 2002).



# I. EMCV $\Delta$ 2A production and characterization

---


One-step growth cycle




# I. EMCV $\Delta$ 2A production and characterization

---

Plaque assay on BHK-21



EMCV



EMCV  $\Delta$ 2A

# Plan

---

## Introduction

Why a recombinant vaccine EMCV-FMDV?

## Results

- I. production and characterization of EMCVΔ2A
- II. Virulence attenuation on human primary astrocytes
- III. Virulence attenuation on mice
- IV. Production EMCV-FMDV

## Conclusion

---

## II. Virulence att. on human primary astrocytes

---

### EMCV

Able to infect a wide range of animal species.


Has been described to possibly infect and cause of head ache, vomiting, malaise, fever... In Human.

(Oberste *et al*, *Emerg Inf Dis* 2009)

**Test infectivity of Human primary astrocytes by EMCV,  
and the attenuation of EMCV $\Delta$ 2A.**


## II. Virulence att. on human primary astrocytes

**EMCV** can infect and replicate on human primary astrocytes





EMCV

Astrocytes 5hpi




EMCV $\Delta$ 2A



**EMCV $\Delta$ 2A** is able to infect and replicate on human primary astrocytes but less efficiently.

## II. Virulence att. on human primary astrocytes



**EMCV $\Delta$ 2A virus is less virulent than the wild type on Human primary Astrocytes**

# Plan

---

## Introduction

Why a recombinant vaccine EMCV-FMDV?

## Results

- I. production and characterization of EMCVΔ2A
- II. Virulence attenuation on human primary astrocytes
- III. Virulence attenuation on mice
- IV. Production EMCV-FMDV


## Conclusion

---


## II. Virulence attenuation on mice

---

Intraperitoneally inoculation



### III. Virulence attenuation on mice




EMCV $\Delta$ 2A does not induce any clinical sign in C57BL/6 mice

### III. Virulence attenuation on mice

Number of viral RNA copy:


in mice heart.



Detection of **EMCV Δ2A** in mice heart only at 3dpi 1 out of 5 mice heart & at 9dpi in 3 out of 5. No more at 22dpi.

=>**EMCV Δ2A** is able to replicate *in vivo*.

in mice CNS.



EMCV Δ2A does not reach the mice CNS.

# Conclusion sur EMCV $\Delta$ 2A

---

Virulence attenuation of EMCV $\Delta$ 2A :

on BHK-21

on human primary astrocytes

(With first demonstration of human primary astrocytes sensitivity to EMCV.)

on mice

The EMCV $\Delta$ 2A virus is an attenuated virus,

Which should be a safe base for a recombinant EMCV-FMDV vaccine.

# Plan

---

## Introduction

Why a recombinant vaccine EMCV-FMDV?


## Results

- I. production and characterization of EMCVΔ2A
- II. Virulence attenuation on human primary astrocytes
- III. Virulence attenuation on mice
- IV. Production EMCV-FMDV

## Conclusion


---

## IV. Production of EMCV $\Delta$ 2A-P1FMDV







## IV. Production of EMCV $\Delta$ 2A-P1FMDV

---



## IV. Production of EMCV $\Delta$ 2A-P1FMDV

---



# Conclusion

---

Virulence attenuation of EMCVΔ2A :

on BHK-21

on human primary astrocytes

(With first demonstration of human primary astrocytes sensitivity to EMCV.)

on mice

The EMCVΔ2A virus safe base for a recombinant.

Transfection of pMC1 (recombinant cDNA):

Cytopathic effects and expression of P1-FMDV  
viral particle production ?

**To be confirmed...**

# Acknowledgements



UMR 1161 (ANSES,ENVA,INRA)  
Maisons-Alfort, FRANCE



*Stephan Zientara,  
Labib Bakkali Kassimi,  
Monique Guy.  
Muriel Couplier.*



**Building Bridges Workshop**

**Beijing, 2-4 July 2011**



**Thank you for your attention !**

***Promoting Scientific Cooperation between China  
and Europe to Combat Epizootic Diseases***